• Redx announces sale of KRAS inhibitor program

    Read more
  • Redx Annual Results December 2023

    Read more
  • Admission of Subscription Shares and TVR

    Read more
  • Results of General Meeting

    Read more
  • Redx Unveils Preclinical Data from RXC009

    Read more
  • Redx to present preclinical data on RXC009 at ASN

    Read more
  • Confirmation of Directorate Change

    Read more
  • Directorate Change

    Read more
  • Zelasudil granted FDA Orphan Drug Designation

    Read more
  • Directorate Change

    Read more